Overview

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Status:
RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Intra-Cellular Therapies, Inc.